Galderma Launches Alastin ® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market
10.9.2025 07:00:00 CEST | Business Wire | Press Release
Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one of the world’s fastest growing aesthetic skincare markets.6-8 This is the first launch to feature Alastin by Galderma’s new re-energized, premium look and feel, a bold evolution that reflects its leadership in perioperative skincare.
Alastin offers full-spectrum care for patients undergoing aesthetic procedures, from pre-treatment preparation to post-treatment recovery and at-home maintenance, supporting the skin’s natural regenerative abilities to improve overall skincare results.1,2,9-13 With over 50 global dermatological publications and 22 patents, Alastin is strongly backed by science and is the number one peri-procedural skincare brand in the United States.14-16 This launch follows the strong growth of Alastin in other key markets and demonstrates Galderma’s commitment to addressing the needs of patients with science-backed solutions.
“With Alastin by Galderma, we have a comprehensive perioperative solution to enhance skin recovery around aesthetic treatment and maintenance programs that bring together Galderma’s leading expertise in Dermatological Skincare and Injectable Aesthetics. As the Asia-Pacific region’s beauty and aesthetics market continues to grow at pace, we’re proud to bring Alastin to patients in China who are seeking advanced solutions to support them in their aesthetic journeys.”
|
Comprehensive perioperative solutions addressing growing needs
Four core Alastin products that cover all stages of the aesthetic treatment process will now be available in China, creating an integrated in-clinic and at-home skincare program:
- Regenerating Skin Nectar to optimize visible treatment results9
- HA (Hyaluronic Acid) IMMERSE Serum™ to hydrate and support skin barrier repair10
- INhance Serum helps to enable quicker recovery after treatment with injectables, improving the appearance of the skin post-injection11
- Restorative Skin Complex to support aesthetic treatment results by helping to reduce the visible signs of aging12
This comprehensive perioperative series of regenerative skincare products advances aesthetic treatments from isolated procedures to full-spectrum management.1,2,9-12 It reflects Galderma’s holistic approach to aesthetic care – working across its Dermatological Skincare and Injectable Aesthetics portfolios to ensure that products complement each other, delivering seamless, science-backed solutions that elevate patient outcomes.1,2,9-13 Select products are powered by proprietary TriHex Technology® to further enhance skin regeneration and recovery.1,2,13
China’s medical aesthetics market is experiencing remarkable growth, and is projected to increase by up to 15% in the next decade.17 As aesthetic treatments become increasingly mainstream there is rising demand for perioperative skincare, with consumers willing to invest in advanced technologies and premium products to achieve optimal aesthetic outcomes.3-6,17 With its proven efficacy and full-spectrum approach to pre- and post-procedure care, as well as at-home maintenance, Alastin by Galderma is uniquely positioned to address this need.1,2,6-9
“We’re seeing an incredible rise in demand for aesthetic procedures in China, and with that comes a growing need for effective perioperative skincare. Alastin by Galderma brings a scientifically advanced approach to skin recovery, and I’m excited to see Chinese patients gain access to products that can truly support their skin before and after treatment, and elevate their overall results.”
|
This launch marks ten years of pioneering innovation with Alastin, demonstrating Galderma’s commitment to purposeful growth with the brand’s refreshed premium look and feel, and entry into one of the fastest growing aesthetic skincare markets. Following strong growth in North America, Latin America, Australia, and the U.K. & Ireland, Alastin is now undergoing rapid international expansion, offering its premium products to even more patients. By identifying emerging patient needs and delivering science-backed solutions, Galderma continues to shape the future of dermatology and elevate outcomes across the aesthetic journey.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References | |
1. | Widgerow AD, et al. Extracellular Matrix Modulation: Optimizing Skin Care and Rejuvenation Procedures. J Drugs Dermaol. 2016;15(Suppl 4):s63–71. |
2. | Widgerow AD, et al. Preoperative Skin Conditioning: Extracellular Matrix Clearance and Skin Bed Preparation, A New Paradigm. Aesthetic Surgery Journal 2019;39(Suppl 3):s103–11. doi:10.1093/asj/sjz022 |
3. | Guidepoint Qsight. From Gen Z to GLP-1s: Trends Reshaping the Medical Aesthetics Industry. Accessed September 2025. Available online. |
4. | Verified Market Reports. Preoperative Skin Preparation Market. Accessed September 2025. Available online. |
5. | PW Consulting Health Care Research Center. Post Procedure Skin Care Product Market. Accessed September 2025. Available online. |
6. | Kwon SH, et al. Experiences and attitudes toward aesthetic procedures in East Asia: a cross-sectional survey of five geographical regions. Arch Plast Surg. 2021;48(6):660-669. doi: 10.5999/aps.2020.02565. |
7. | Fortune Business Insights. China Skincare Market Size, Share & Industry Analysis. Accessed September 2025. Available online. |
8. | Mordor Intelligence. China Cosmetic Products Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030). Accessed September 2025. Available online. |
9. | Alastin. Regenerating Skin Nectar with TriHex Technology®. Accessed September 2025. Available online. |
10. | Alastin. HA (Hyaluronic Acid) IMMERSE Serum™. Accessed September 2025. Available online. |
11. | Alastin. INhance Post-Injection Serum with TriHex Technology®. Accessed September 2025. Available online. |
12. | Alastin. Restorative Skin Complex with TriHex Technology®. Accessed September 2025. Available online. |
13. | Lee WW, et al. A Multi-Center Evaluation of Restorative Eye Treatment and INhance With Trihex Technology to Improve Aesthetic Outcomes When Used Pre- and Post-Blepharoplasty. Aesthet Surg J Open Forum. 2022 Dec 14;5:ojac089. doi: 10.1093/asjof/ojac089. |
14. | Galderma. Data on File. Alastin Publication List. |
15. | Galderma. Data on File. Alastin Patent List. |
16. | Galderma. Data on File. LifeSci Consulting Primary Market Research. 2022. |
17. | Chameleon Pharma. China’s Dynamic Aesthetic Medicine Market: Outlook, Trends, and Opportunities. Accessed September 2025. Available online. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909403223/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom